Silvia Marino
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Associate Staff Scientist
Also affiliated: Indiana University Health (2019–2020); Western General Hospital (2012–2020); Edinburgh Cancer Research (2012–2021); Moffitt Cancer Center (2025); Institute of Genetics and Cancer (2012–2021); Indiana University School of Medicine (2017–2023); Indiana University – Purdue University Indianapolis (2017–2025); University of Sheffield (2014–2021); University of Edinburgh (2012)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Silvia Marino's research investigates the complex interactions between multiple myeloma and bone, focusing on mechanisms that drive osteolysis and skeletal tumor growth. Her work has explored the role of cannabinoid receptors, specifically CNR1 and CNR2, in protecting against age-related bone loss and inhibiting osteoclasts. Marino has also examined the impact of monoacylglycerol lipase inhibitors on bone remodeling in both healthy and cancer-bearing mice, noting paradoxical effects. Her research extends to understanding how TRAF2 in breast cancer cells contributes to skeletal tumor progression and osteolysis. Marino has published on generating and culturing osteoclasts, as well as on ex vivo explant culture models for bone research. Her scholarship metrics include an h-index of 17, with 48 total publications and 747 total citations.
Metrics
- h-index: 17
- Publications: 48
- Citations: 747
Positions
-
Associate Staff Scientist 2021–presentUniversity of Arkansas for Medical Sciences Physiology and Cell Biology ORCID
Selected Publications
-
DMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor (2026)
-
Loss of PTH 1 receptor signaling in periodontal cells drives cementum dysfunction and molar ankylosis in mice (2026)
-
2D and 3D In Vitro Co-culture for Cancer and Bone Cell Interaction Studies (2025)
-
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss (2024)
-
Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation (2024)
Collaboration Network
Top Collaborators
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Loss of PTH 1 receptor signaling in periodontal cells drives cementum dysfunction and molar ankylosis in mice
- DMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Loss of PTH 1 receptor signaling in periodontal cells drives cementum dysfunction and molar ankylosis in mice
- DMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
Similar Researchers
Based on overlapping research topics